Skip to main content

Table 1 Influence of the 21-gene assay on adjuvant chemotherapy recommendations

From: Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan

Patient population* Patients recommended by physicians to adjuvant chemotherapy, n (%)
Prior to assay After assay Change
All 48 (46.2) 28 (26.9) −20 (−19.2)
Low-risk 16 (32.0) 0 (0.0) −16 (−32.0)
Intermediate-risk 18 (48.6) 11 (29.7) −7 (−18.9)
High-risk 14 (82.4) 17 (100.0) 3 (17.6)
  1. *Risk group determined by the 21-gene assay. Risk groups: zero to 17 is low-risk, 18 to 30 is intermediate-risk, greater than 30 is high-risk.
  2. Source: Yamauchi et al. Clin Breast Cancer 2013 [18].